| 2022-12-19 | +292.6% | legal | SEC EDGAR | MDGL 8-K: 7.01 and 8.01 (SEC Filing) |
| 2024-10-31 | +49.5% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2022-08-04 | +23.1% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-01-13 | -19.4% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-03-25 | +17.8% | earnings | MarketBeat | JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat |
| 2024-03-15 | +16.7% | legal | SEC EDGAR | MDGL 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-04 | +16.2% | news | Seeking Alpha | Madrigal projects Rezdiffra annualized sales over $1B while expanding payer access and pipeline in 2026 |
| 2025-11-04 | +16.2% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | +16.2% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. GAAP EPS of -$5.08 misses by $2.59, revenue of $287.3M beats by $39.6M |
| 2025-11-04 | +16.2% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | +16.2% | earnings | Yahoo Finance | Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance |
| 2025-11-04 | +16.2% | news | Yahoo Finance | Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - Yahoo Finance |
| 2025-11-04 | +16.2% | earnings | Stock Titan | Madrigal Pharmaceuticals (NASDAQ: MDGL) reports $287.3M Q3 sales, up from $62.2M - Stock Titan |
| 2026-03-26 | +14.0% | earnings | Zacks | Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report? |
| 2026-03-26 | +14.0% | news | Zacks | ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms |
| 2026-03-26 | +14.0% | news | Seeking Alpha | Stocks to watch after market on Thursday: MDGL, M, MODD |
| 2026-03-26 | +14.0% | M&A | Seeking Alpha | Madrigal Pharmaceuticals gains amid renewed takeover speculation |
| 2026-03-26 | +14.0% | news | TipRanks | Why Madrigal Pharmaceuticals Stock Is Breaking Out Now - TipRanks |
| 2026-03-26 | +14.0% | M&A | Stocktwits | MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits |
| 2026-03-26 | +14.0% | news | Seeking Alpha | Stocks to watch after market on Thursday: MDGL, M, MODD (M:NYSE) - Seeking Alpha |
| 2026-02-19 | -11.9% | news | Seeking Alpha | Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge |
| 2026-02-19 | -11.9% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript |
| 2026-02-19 | -11.9% | earnings | Seeking Alpha | Madrigal down after wider-than-expected Q4 loss |
| 2026-02-19 | -11.9% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. GAAP EPS of -$2.57 misses by $2.03, revenue of $321.08M beats by $8.34M |
| 2026-02-19 | -11.9% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-02-19 | -11.9% | earnings | Quiver Quantitative | MADRIGAL PHARMACEUTICALS ($MDGL) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2026-02-19 | -11.9% | earnings | Yahoo Finance | Madrigal Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance |
| 2026-02-19 | -11.9% | earnings | Seeking Alpha | Madrigal down on wider-than-expected Q4 loss (MDGL:NASDAQ) - Seeking Alpha |
| 2026-02-19 | -11.9% | news | Stock Titan | Nearly $1B from first EU-approved MASH drug: inside Rezdiffra’s 2025 surge - Stock Titan |
| 2026-02-19 | -11.9% | earnings | Investing.com | Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com |
| 2026-02-19 | -11.9% | earnings | Investing.com | Madrigal Pharma shares fall over 5% as Q4 earnings miss overshadows revenue beat - Investing.com |
| 2024-05-07 | -11.8% | legal | SEC EDGAR | MDGL 8-K: 1.01, 1.02, 8.01 (SEC Filing) |
| 2024-05-07 | -11.8% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-05 | +10.6% | expansion | Seeking Alpha | Madrigal upgraded at Cantor on Rezdiffra launch |
| 2025-11-05 | +10.6% | earnings | Yahoo Finance | Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance |
| 2025-11-05 | +10.6% | earnings | simplywall.st | Madrigal Pharmaceuticals (MDGL): Forecasts Point to 34.8% Annual Revenue Growth Ahead of Earnings - simplywall.st |
| 2026-02-18 | -10.6% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Preview |
| 2024-08-07 | -10.2% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-02-26 | +10.0% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-12-19 | +9.5% | news | Yahoo Finance | Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge - Yahoo Finance |
| 2022-12-23 | -9.3% | legal | SEC EDGAR | MDGL 8-K: 1.01, 5.03, 7.01, 8.01 (SEC Filing) |
| 2026-01-09 | -9.0% | M&A | Seeking Alpha | Pfizer inks licensing deal with Madrigal for MASH candidate |
| 2026-01-09 | -9.0% | news | Seeking Alpha | Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha |
| 2026-01-09 | -9.0% | news | Stock Titan | Drug combo planned to target liver fat in patients with MASH - Stock Titan |
| 2025-07-22 | -8.2% | legal | SEC EDGAR | MDGL 8-K: 1.01, 1.02, 2.03, 7.01 (SEC Filing) |
| 2025-08-05 | +8.1% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-05-01 | -7.7% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-17 | +7.4% | news | Stock Titan | Madrigal Pharma (NASDAQ: MDGL) sets fireside chats at three investor conferences - Stock Titan |
| 2026-01-05 | -7.3% | news | Seeking Alpha | Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data |
| 2025-11-03 | +7.1% | earnings | Seeking Alpha | Madrigal Pharmaceuticals Q3 2025 Earnings Preview |
| 2025-11-03 | +7.1% | analyst | Seeking Alpha | Madrigal Pharmaceuticals upgraded at BofA on Rezdiffra uptake |
| 2022-11-03 | -7.1% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2023-09-14 | -6.9% | legal | SEC EDGAR | MDGL 8-K: 5.02 and (SEC Filing) |
| 2024-01-08 | +6.7% | legal | SEC EDGAR | MDGL 8-K: 8.01 and (SEC Filing) |
| 2021-08-05 | +6.7% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2021-06-01 | -6.6% | legal | SEC EDGAR | MDGL 8-K: 1.01 and (SEC Filing) |
| 2025-08-15 | +5.7% | expansion | Seeking Alpha | Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further (NASDAQ:MDGL) - Seeking Alpha |
| 2025-11-24 | +5.6% | M&A | Stocktwits | Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - Stocktwits |
| 2025-11-24 | +5.6% | M&A | MSN | Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN |
| 2023-05-09 | -5.4% | legal | SEC EDGAR | MDGL 8-K: 1.01 and (SEC Filing) |
| 2023-05-09 | -5.4% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-04-07 | -5.2% | earnings | MarketBeat | Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat |
| 2026-04-07 | -5.2% | news | Stock Titan | 20 new Madrigal hires get stock awards that vest over four years - Stock Titan |
| 2024-03-20 | -5.2% | legal | SEC EDGAR | MDGL 8-K: 1.01 and (SEC Filing) |
| 2026-02-17 | +5.1% | earnings | Seeking Alpha | Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday |
| 2026-02-17 | +5.1% | earnings | Seeking Alpha | Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday - Seeking Alpha |
| 2025-10-21 | -4.9% | news | Stock Titan | Madrigal Pharma (NASDAQ: MDGL) grants 8,581 RSUs and 889 options to new hires - Stock Titan |
| 2026-01-06 | -4.9% | news | The Motley Fool | Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - The Motley Fool |
| 2026-01-06 | -4.9% | analyst | Investing.com | Wolfe Research downgrades Madrigal Pharmaceuticals stock on valuation concerns - Investing.com |
| 2023-08-08 | -4.9% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2023-02-23 | -4.8% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2021-06-21 | -4.8% | legal | SEC EDGAR | MDGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2026-02-15 | +4.7% | news | Yahoo Finance | Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility - Yahoo Finance |
| 2025-12-11 | +4.3% | legal | SEC EDGAR | MDGL 8-K: 5.02 (SEC Filing) |
| 2025-09-28 | +4.2% | news | Seeking Alpha | Goldman's 48 potential M&A candidates |
| 2022-02-24 | +4.1% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2023-07-17 | -3.9% | legal | SEC EDGAR | MDGL 8-K: 8.01 and (SEC Filing) |
| 2026-01-22 | -3.9% | news | Stock Titan | Biotech Madrigal gives 3,049 options, 13,145 RSUs to new staff - Stock Titan |
| 2026-01-22 | -3.9% | news | Quiver Quantitative | Lobbying Update: $280,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative |
| 2026-01-12 | -3.9% | news | Stock Traders Daily | How Madrigal Pharmaceuticals Inc. (MDGL) Affects Rotational Strategy Timing - Stock Traders Daily |
| 2025-11-06 | +3.8% | earnings | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Losses Worsen, Profitability Forecast Sparks Debate on Valuation Narratives - Yahoo Finance |
| 2025-12-01 | -3.7% | expansion | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Yahoo Finance |
| 2025-12-01 | -3.7% | earnings | DirectorsTalk Interviews | Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A High-Flying Biotech With 362% Revenue Growth - DirectorsTalk Interviews |
| 2026-04-01 | +3.6% | news | Investing.com | Wolfe Research reiterates Peerperform on Madrigal stock - Investing.com |
| 2024-04-02 | -3.6% | legal | SEC EDGAR | MDGL 8-K: 8.01 (SEC Filing) |
| 2026-04-23 | -3.5% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | MDGL Madrigal Pharmaceuticals reports 432 percent Q4 2025 revenue growth, wider than expected losses send shares down 1.3 percent. - Miss Estimates - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-23 | -3.5% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Madrigal Pharmaceuticals (MDGL) Stock Movers | Q4 2025: Earnings Fall Short - Regulatory Risk - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-11-12 | -3.3% | earnings | simplywall.st | Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 26% Price Boost Is Out Of Tune With Revenues - simplywall.st |
| 2026-01-26 | +3.2% | news | Investing.com | Taub, Madrigal Pharmaceuticals director, sells $318k in shares - Investing.com |
| 2021-05-18 | -3.2% | legal | SEC EDGAR | MDGL 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-09-08 | +3.2% | news | Seeking Alpha | Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) |
| 2025-08-13 | +3.1% | analyst | simplywall.st | Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - simplywall.st |
| 2026-01-21 | -3.1% | M&A | Stock Titan | New accounting chief at Madrigal lands stock and options deal - Stock Titan |
| 2023-11-06 | +3.0% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | +3.0% | news | Yahoo Finance | Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge? - Yahoo Finance |
| 2025-12-05 | -2.9% | expansion | Yahoo Finance | Madrigal Pharmaceuticals (MDGL): Rezdiffra’s Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation - Yahoo Finance |
| 2026-04-04 | -2.9% | earnings | MarketBeat | Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat |
| 2022-05-09 | +2.7% | legal | SEC EDGAR | MDGL 8-K: 1.01, 2.03and3.02 (SEC Filing) |
| 2022-05-09 | +2.7% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2025-08-25 | +2.5% | news | Yahoo Finance | Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance |
| 2026-04-22 | -2.3% | news | GlobeNewswire | Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 |
| 2026-04-22 | -2.3% | earnings | Stock Titan | Madrigal posts Q1 results May 6, then briefs investors at 8 a.m. - Stock Titan |
| 2026-02-04 | -2.2% | analyst | Investing.com | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com |
| 2023-10-02 | -2.2% | legal | SEC EDGAR | MDGL 8-K: 1.01 and (SEC Filing) |
| 2026-02-24 | -2.2% | news | GlobeNewswire | Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire |
| 2025-10-26 | +2.2% | news | Seeking Alpha | Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth |
| 2025-10-26 | +2.2% | news | Seeking Alpha | Madrigal Pharmaceuticals: Rezdiffra Commercialization Bode Well For Continued Growth MDGL - Seeking Alpha |
| 2025-07-25 | -2.1% | news | Yahoo Finance | Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - Yahoo Finance |
| 2024-06-27 | +2.0% | legal | SEC EDGAR | MDGL 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-04-17 | -1.9% | legal | SEC EDGAR | MDGL 8-K: 5.02 (SEC Filing) |
| 2025-12-03 | +1.9% | news | Investing.com | Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com |
| 2023-09-13 | -1.8% | legal | SEC EDGAR | MDGL 8-K: 5.02 and (SEC Filing) |
| 2023-09-13 | -1.8% | legal | SEC EDGAR | MDGL 8-K: 8.01 and (SEC Filing) |
| 2023-09-25 | -1.8% | legal | SEC EDGAR | MDGL 8-K: 5.02 (SEC Filing) |
| 2026-03-19 | +1.8% | news | Stock Titan | Seven new Madrigal hires get stock awards that vest over 4 years - Stock Titan |
| 2024-02-28 | -1.7% | legal | SEC EDGAR | MDGL 8-K: 5.02 (SEC Filing) |
| 2024-02-28 | -1.7% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-01-03 | -1.6% | analyst | Seeking Alpha | Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade |
| 2026-01-03 | -1.6% | analyst | Seeking Alpha | Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade - Seeking Alpha |
| 2025-08-08 | +1.5% | earnings | simplywall.st | Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st |
| 2025-10-22 | -1.5% | earnings | Yahoo Finance | When Can We Expect A Profit From Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)? - Yahoo Finance |
| 2025-10-22 | -1.5% | news | Quiver Quantitative | Madrigal Pharmaceuticals Schedules Third-Quarter 2025 Financial Results Release and Webcast - Quiver Quantitative |
| 2025-12-17 | -1.5% | M&A | Seeking Alpha | Sagimet rises as licensing deal with Teva unit targets Madrigal drug |
| 2026-02-23 | +1.4% | analyst | Investing.com | H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating at buy - Investing.com |
| 2026-03-05 | +1.4% | news | Stock Titan | 20 new Madrigal staff get stock options and 6,882 RSUs at $432 - Stock Titan |
| 2025-12-20 | +1.4% | analyst | StocksToTrade | Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade |
| 2021-11-04 | -1.4% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2023-06-30 | +1.2% | legal | SEC EDGAR | MDGL 8-K: 8.01 and (SEC Filing) |
| 2026-01-30 | -1.2% | legal | SEC EDGAR | MDGL 8-K: 1.01 and (SEC Filing) |
| 2026-03-31 | +1.2% | earnings | MarketBeat | Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat |
| 2026-04-16 | +1.1% | news | Motley Fool | 3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist |
| 2026-02-02 | -1.0% | news | Quiver Quantitative | Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative |
| 2026-02-25 | +1.0% | news | Seeking Alpha | Madrigal: The Easiest Money May Have Been Made |
| 2026-02-25 | +1.0% | news | Yahoo Finance | Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance |
| 2026-02-25 | +1.0% | news | Seeking Alpha | Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha |
| 2026-03-06 | -1.0% | executive | Investing.com | Madrigal Pharmaceuticals CEO Sibold sells $718k in shares - Investing.com |
| 2026-01-27 | -0.9% | news | Yahoo Finance | Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Recent Share Price Pullback? - Yahoo Finance |
| 2021-05-06 | -0.9% | legal | SEC EDGAR | MDGL 8-K: 2.02 and (SEC Filing) |
| 2026-02-05 | -0.9% | news | Stock Titan | 21 new Madrigal hires receive 5,861 stock units vesting over 4 years - Stock Titan |
| 2025-11-18 | +0.9% | news | Yahoo Finance | Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance |
| 2025-11-18 | +0.9% | news | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis - Yahoo Finance |
| 2026-01-10 | -0.8% | M&A | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed - Yahoo Finance |
| 2026-01-10 | -0.8% | news | Yahoo Finance | Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Yahoo Finance |
| 2025-11-20 | -0.8% | news | Seeking Alpha | Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript |
| 2025-11-20 | -0.8% | news | Stock Titan | Madrigal Pharmaceuticals (NASDAQ: MDGL) grants 2,125 RSUs to hires under inducement plan - Stock Titan |
| 2025-12-23 | -0.8% | news | Seeking Alpha | Here are the most and least likely M&A targets in biotech, according to Truist |
| 2026-03-07 | -0.8% | news | Investing.com | Madrigal Pharmaceuticals EVP Dier sells $854k in stock - Investing.com |
| 2026-04-08 | -0.7% | news | simplywall.st | Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Rezdiffra Growth Expectations - simplywall.st |
| 2026-04-08 | -0.7% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Should I Buy Madrigal Pharmaceuticals (MDGL) Stock Now | Price at $509.19, Down 0.53% - Institutional Flow - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-29 | -0.7% | M&A | simplywall.st | Madrigal Expands Beyond Rezdiffra With New RNA Licensing Deal - simplywall.st |
| 2025-12-04 | -0.7% | earnings | Yahoo Finance | Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance |
| 2025-09-30 | +0.6% | news | Seeking Alpha | Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising |
| 2025-09-30 | +0.6% | news | Seeking Alpha | Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising (NASDAQ:MDGL) - Seeking Alpha |
| 2026-01-14 | +0.6% | analyst | Investing.com | Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs - Investing.com |
| 2026-03-02 | -0.6% | news | Stock Titan | Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan |
| 2026-04-17 | -0.6% | news | Seeking Alpha | Most shorted large cap stocks as of mid-April |
| 2026-03-27 | -0.6% | news | Insider Monkey | Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug |
| 2026-03-27 | -0.6% | earnings | Zacks | United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue? |
| 2026-03-27 | -0.6% | news | Zacks | Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? |
| 2026-03-27 | -0.6% | news | Simply Wall St. | Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? |
| 2026-03-27 | -0.6% | news | Yahoo Finance | Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Yahoo Finance |
| 2026-03-27 | -0.6% | news | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Yahoo Finance |
| 2026-03-27 | -0.6% | news | Yahoo Finance | Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance |
| 2026-03-27 | -0.6% | news | Stock Titan | Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan |
| 2026-04-09 | -0.5% | news | simplywall.st | Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - simplywall.st |
| 2026-02-20 | +0.5% | earnings | Seeking Alpha | Madrigal Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-20 | +0.5% | earnings | Finviz | Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz |
| 2026-02-11 | +0.5% | M&A | Seeking Alpha | Madrigal inks licensing deal with Chinas Suzhou Ribo for MASH drugs |
| 2026-02-11 | +0.5% | M&A | Seeking Alpha | Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - Seeking Alpha |
| 2026-02-11 | +0.5% | news | Stock Titan | Madrigal signs RNA liver drug pact with Ribo worth up to $4.4B - Stock Titan |
| 2026-01-13 | -0.3% | news | Seeking Alpha | Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-13 | -0.3% | news | Investing.com | Rebecca Taub sells Madrigal (MDGL) shares worth $9.6 million - Investing.com |
| 2026-01-13 | -0.3% | news | Investing.com | Director Friedman sells Madrigal (MDGL) shares for $154,347 - Investing.com |
| 2023-02-09 | -0.3% | legal | SEC EDGAR | MDGL 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2023-06-20 | -0.3% | legal | SEC EDGAR | MDGL 8-K: 5.02 (SEC Filing) |
| 2025-03-11 | -0.3% | legal | SEC EDGAR | MDGL 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-02 | +0.2% | M&A | Seeking Alpha | Trump imposes tariffs on drugmakers who haven't signed MFN deals |
| 2026-04-11 | +0.2% | news | Simply Wall St. | Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge? |
| 2026-04-11 | +0.2% | news | Yahoo Finance | Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge? - Yahoo Finance |
| 2023-01-10 | -0.2% | legal | SEC EDGAR | MDGL 8-K: 8.01 (SEC Filing) |
| 2026-03-10 | -0.1% | news | Yahoo Finance | What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy - Yahoo Finance |
| 2026-03-30 | -0.1% | news | simplywall.st | Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - simplywall.st |
| 2026-04-20 | +0.0% | news | DirectorsTalk Interviews | Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: 26% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews |
| 2026-04-20 | +0.0% | news | Cổng thông tin điện tử tỉnh Lào Cai | Madrigal Pharmaceuticals (MDGL) Stock: Is It Approaching Breakout Zone (-0.71%) 2026-04-20 - Real Trader Network - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-21 | +0.0% | news | GlobeNewswire | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-21 | +0.0% | news | Stock Titan | 12 new Madrigal hires get stock awards that vest over four years - Stock Titan |
| 2026-01-20 | -0.0% | expansion | Investing.com | Citizens raises Madrigal Pharmaceuticals stock price target on strong Rezdiffra launch - Investing.com |
| 2026-03-03 | -0.0% | earnings | Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Yahoo Finance |
| 2026-03-03 | -0.0% | earnings | Finviz | Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz |
| 2026-04-26 | — | earnings | MarketBeat | Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat |